Nifty
:
17196.70
Sensex
:
57696.46
-204.95 (-1.18%)
-764.83 (-1.31%)
Nifty
Sensex
:
:
17196.70
57696.46
-204.95 (-1.18%)
-764.83 (-1.31%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
53/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
751.80
03-Dec-2021
  • Open
  • High
  • Low
  • Previous Close
  •  771.90
  •  771.90
  •  748.90
  •  766.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3135454
  •  23661.98
  •  851.00
  •  539.70

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 180,382.00
  • 29.00
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 177,703.40
  • 1.00%
  • 3.65

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 3.19%
  • 6.79%
  • FII
  • DII
  • Others
  • 12.07%
  • 21.31%
  • 2.16%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.37
  • 1.36
  • 4.84

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.28
  • -2.64
  • 6.18

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.93
  • -15.96
  • 3.02

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 39.10
  • 34.61
  • 33.77

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.67
  • 3.16
  • 2.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.78
  • 15.85
  • 15.56

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
9,625.93
8,553.13
12.54%
9,718.74
7,585.25
28.13%
8,522.98
8,184.94
4.13%
8,836.78
8,154.85
8.36%
Expenses
6,995.99
6,359.85
10.00%
6,977.54
5,820.90
19.87%
6,474.54
6,821.93
-5.09%
6,502.27
6,395.25
1.67%
EBITDA
2,629.94
2,193.28
19.91%
2,741.20
1,764.35
55.37%
2,048.44
1,363.01
50.29%
2,334.51
1,759.60
32.67%
EBIDTM
27.32%
25.64%
28.21%
23.26%
24.03%
16.65%
26.42%
21.58%
Other Income
222.89
255.78
-12.86%
232.40
232.95
-0.24%
111.00
102.23
8.58%
386.58
201.68
91.68%
Interest
35.95
33.28
8.02%
35.09
51.95
-32.45%
30.10
51.78
-41.87%
26.10
62.96
-58.55%
Depreciation
530.37
498.60
6.37%
503.22
495.92
1.47%
553.49
575.38
-3.80%
531.94
546.99
-2.75%
PBT
2,286.51
1,917.18
19.26%
1,804.22
-2,183.90
-
903.04
577.44
56.39%
2,163.05
1,351.33
60.07%
Tax
197.78
-31.20
-
395.57
245.91
60.86%
55.04
83.09
-33.76%
244.94
327.62
-25.24%
PAT
2,088.73
1,948.38
7.20%
1,408.65
-2,429.81
-
848.00
494.35
71.54%
1,918.11
1,023.71
87.37%
PATM
21.70%
22.78%
14.49%
-32.03%
9.95%
6.04%
21.71%
12.55%
EPS
8.53
7.56
12.83%
6.02
-6.90
-
3.73
1.67
123.35%
7.72
3.81
102.62%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
36,704.43
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
Net Sales Growth
13.01%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
 
Cost Of Goods Sold
9,745.44
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
Gross Profit
26,958.99
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
GP Margin
73.45%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
Total Expenditure
26,950.34
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
Power & Fuel Cost
-
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
145.65
% Of Sales
-
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
Employee Cost
-
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
% Of Sales
-
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
Manufacturing Exp.
-
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
% Of Sales
-
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
General & Admin Exp.
-
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
% Of Sales
-
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
Selling & Distn. Exp.
-
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
% Of Sales
-
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
Miscellaneous Exp.
-
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
464.95
516.55
% Of Sales
-
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
EBITDA
9,754.09
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
EBITDA Margin
26.57%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
Other Income
952.87
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
Interest
127.24
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
Depreciation
2,119.02
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
PBT
7,156.82
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
Tax
893.33
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
313.19
Tax Rate
12.48%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
PAT
6,263.49
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
PAT before Minority Interest
6,255.10
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
Minority Interest
-8.39
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
PAT Margin
17.06%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
PAT Growth
504.22%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
12.48%
 
EPS
26.11
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46
11.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
Share Capital
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
103.56
Total Reserves
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
Non-Current Liabilities
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
Secured Loans
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
41.90
49.65
Unsecured Loans
890.30
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
Long Term Provisions
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
Current Liabilities
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
Trade Payables
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
Other Current Liabilities
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
Short Term Borrowings
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
Short Term Provisions
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
Total Liabilities
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
Net Block
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
Gross Block
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
Accumulated Depreciation
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
Non Current Assets
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
Capital Work in Progress
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
Non Current Investment
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
Long Term Loans & Adv.
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
Other Non Current Assets
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
42.90
18.71
Current Assets
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
Current Investments
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
Inventories
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
Sundry Debtors
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
Cash & Bank
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
Other Current Assets
2,808.09
1,541.48
1,266.30
891.31
3,546.51
2,847.64
5,026.16
3,774.42
1,149.11
1,136.55
Short Term Loans & Adv.
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
Net Current Assets
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
Total Assets
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
PBT
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
Adjustment
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
Changes in Working Capital
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
Cash after chg. in Working capital
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
Net Fixed Assets
-697.67
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
Net Investments
363.04
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
Others
870.85
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
Cash from Financing Activity
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
Net Cash Inflow / Outflow
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
Opening Cash & Equivalents
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
Closing Cash & Equivalent
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
59.08
ROA
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
19.61%
22.00%
ROE
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
25.53%
28.02%
ROCE
5.67%
10.08%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
31.39%
30.13%
Fixed Asset Turnover
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
1.51
1.38
Receivable days
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
71.46
71.49
Inventory Days
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
74.22
80.31
Payable days
58.14
59.40
77.81
90.19
85.47
75.24
52.05
56.33
65.15
64.51
Cash Conversion Cycle
46.84
45.22
24.13
12.23
76.75
78.34
54.14
59.31
80.53
87.29
Total Debt/Equity
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
Interest Cover
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13
120.02

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Sun Pharma’s arm settles case with Biofrontera
    1st Dec 2021, 11:05 AM

    Earlier, in 2018, DUSA Pharmaceuticals, Inc has filed a lawsuit against Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG

    Read More
  • Sun Pharmaceutical recalling over 1.10 lakh bottles of generic medication in US market
    22nd Nov 2021, 10:34 AM

    The US arm of the domestic pharma major is recalling Tadalafil tablets in the American market

    Read More
  • Sun Pharma gearing up to introduce molnupiravir in India
    12th Nov 2021, 09:30 AM

    The DCGI is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults in India

    Read More
  • Sun Pharma recalling 22,752 blister packs of Loratadine-D extended-release tablets
    8th Nov 2021, 10:59 AM

    The company is recalling the affected lot due to ‘failed moisture limits’

    Read More
  • Sun Pharmaceutical Industries reports 13% rise in Q2 consolidated net profit
    2nd Nov 2021, 15:12 PM

    Total income of the company increased by 11.81 % at Rs 9,848.82 crore for Q2FY22

    Read More
  • Sun Pharma Inds. - Quarterly Results
    2nd Nov 2021, 13:15 PM

    Read More
  • Sun Pharmaceutical launches Winlevi cream in US market
    1st Nov 2021, 12:16 PM

    Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years

    Read More
  • Sun Pharma launches ILUMYA medicine to treat Plaque psoriasis in Canada
    29th Oct 2021, 12:30 PM

    ILUMYA demonstrates the company’s commitment to providing innovative medicines to support patient lifestyle and physician choice

    Read More
  • Sun Pharmaceutical Industries launches novel formulation in cough management ‘Chericof 12’
    28th Sep 2021, 11:16 AM

    Chericof 12 is approved for patients of age group six years and above

    Read More
  • Sun Pharma forays into nutrition bar segment
    8th Sep 2021, 13:31 PM

    The product has been launched in two different variants, Revital Energy NXT and Revital Protein NXT

    Read More
  • Sun Pharmaceutical sells step-down subsidiary
    2nd Sep 2021, 11:19 AM

    Thus Kayaku Co. has ceased to be the subsidiary of the company with effect from September 1, 2021

    Read More
  • Sun Pharma gets exclusive right to commercialize Winlevi in US, Canada
    1st Sep 2021, 10:15 AM

    Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.